Baggio, B. et al., “Correction of Erythrocyte Abnormalities in Idiopathic Calcium-oxalate Nephrolithiasis and Reduction of Urinary Oxalate by Oral Glycosaminoglycans,” The Lancet, 338:403-405 (1991). |
Drach, G.W., et al., “The Paradox of Inhibition and Enhancement of the Formation of Urinary Stones,” Urological Research, 10(4):165-168 (1982). |
Scurr, D.S., et al., “Polyanionic Inhibitors of Calcium Ozalate Crystal Agglomeration In Urine,” Proc. Eur. Dial. Transplant Assoc. 20:440-444. |
Hodgkinson, A., “Chapter 8. Human and Animal Pathology.” In Ozalic Acid in Biology and Medicine, (London: Academic Press) pp. 244-253, (1977). |
Lindsjö, M. et al., “Treatment of Enteric Hyperoxaluria with Calcium-Contained Organic Marine Hydrocolloid,” The Lancet, Sep. 23, 1989, p. 701-703. |
Smith, L.H., M.D., et al., “Acquired Hyperoxaluria, Nephrolithiasis, and Intestinal Disease,” The New England Journal of Medicine, vol. 286, Jun. 29, 1972, No. 26, p. 1371-1374. |
Hagmaier, V. et al., “Prüfung der Wirksamkeit eines oxalatbindenden Anionenaustauschers Colestid an gesunden Probanden zum Einsatz bei der idiopathischen Calcium-Oxalat-urolithiasis”, Helvetica Chirurgica Acta, 48:421-424 (1981). Abstract in English. |
Patent Abstracts of Japan, vol. 010, No. 063 (C-332), Mar. 13, 1986 & JP 60 202869 A (Ajinomoto KK), Oct. 14, 1985. |
Abstract: WPI Acc. No.: 89-048100/198907. |
Mandeville et al. US patent application Ser. No.: 08/964,956 filed Nov. 5, 1997. |